申请人:Merck & Co., Inc.
公开号:US06011048A1
公开(公告)日:2000-01-04
Thiazole substituted benzenesulfonamides are .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
噻唑取代的苯磺酰胺是β3肾上腺素受体激动剂,对β1和β2肾上腺素受体的活性非常小,因此这些化合物能够增加细胞内的脂解和能量消耗。因此,这些化合物在治疗2型糖尿病和肥胖症方面具有强大的活性。这些化合物还可以用于降低甘油三酯水平和胆固醇水平,或提高高密度脂蛋白水平,或减少肠道运动。此外,这些化合物可以用于减少神经炎症或作为抗抑郁剂。这些化合物是通过将氨基烷基苯磺酰胺与适当取代的环氧化物偶联而制备的。还公开了这些化合物在治疗糖尿病和肥胖症以及降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或减少肠道运动方面的用途的组合物和方法。